ClearPoint Neuro Q3 revenue up 9% driven by new customers

Clearpoint Neuro

06/11/2025 22:41

Overview

ClearPoint Neuro Q3 revenue increased 9% yr/yr but missed analyst expectations

Company announced acquisition of IRRAS Holdings, expanding into neurocritical care

Neurosurgery navigation and therapy revenue rose 20% driven by Prism Laser Therapy sales

Outlook

ClearPoint Neuro reaffirms 2025 revenue guidance between $36.0 mln and $38.0 mln

Company expects 2026 combined revenue with IRRAS to be $54.0 mln to $60.0 mln

Company plans to add 5,000 patient capacity annually for cell and gene therapy trials

Result Drivers

NEW CUSTOMERS - Activated 5 new global customers in Q3, contributing to revenue growth

LABORATORY EXPANSION - Opened ClearPoint Advanced Laboratories, increasing capacity for preclinical studies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$8.90 mln
$9.60 mln (2 Analysts)
Q3 Gross Margin
63.00%
Q3 Operating Expenses
$10.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Clearpoint Neuro Inc is $29.00, about 41.4% above its November 5 closing price of $16.98

Press Release: ID:nACSbGD0Da

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)